公开(公告)号：WO2006026388A2

公开(公告)日：2006-03-09

申请号：PCT/US2005/030329

申请日：2005-08-26

Applicant: GEN-PROBE INCORPORATED ,  BECKER, Michael, M. ,  LAM, Wai-Chung ,  LIVEZEY, Kristin, W. ,  BRENTANO, Steven, T. ,  KOLK, Daniel, P. ,  SCHRODER, Astrid, R.W.

Inventor： BECKER, Michael, M. ,  LAM, Wai-Chung ,  LIVEZEY, Kristin, W. ,  BRENTANO, Steven, T. ,  KOLK, Daniel, P. ,  SCHRODER, Astrid, R.W.

IPC: C12Q1/68 ,  C12P19/34

CPC classification number: C12P19/34 ,  C12Q1/6865 ,  C12Q2537/163 ,  C12Q2521/325 ,  C12Q2521/107 ,  C12Q2525/186 ,  C12Q2533/101 ,  C12Q2525/143

Abstract: The present invention is directed to novel methods of synthesizing multiple copies of a target nucleic acid sequence which are autocatalytic ( i.e ., able to cycle automatically without the need to modify reaction conditions such as temperature, pH, or ionic strength and using the product of one cycle in the next one). In particular, the present invention discloses a method of nucleic acid amplification which is robust and efficient, while reducing the appearance of side-products. The method uses only one primer, the "priming oligonucleotide," a 3'blocked promoter oligonucleotide and optionally, a means for terminating a primer extension reaction, to amplify RNA or DNA molecules in vitro , while reducing or eliminating the formation of side-products. The method of the present invention minimizes or eliminates the emergence of side-products, thus providing a high level of specificity. Furthermore, the appearance of side-products can complicate the analysis of the amplification reaction by various molecular detection techniques. The present invention minimizes or eliminates this problem, thus providing an enhanced level of sensitivity.

Abstract translation: 本发明涉及合成多个拷贝的目标核酸序列的新方法，所述靶核酸序列是自动催化的（<

公开(公告)号：WO2005110622A3

公开(公告)日：2006-01-19

申请号：PCT/US2005015273

申请日：2005-05-03

Applicant: DU PONT ,  BECKER MICHAEL ,  BOSCH WERNER ,  LOTHERT THIMO

Inventor： BECKER MICHAEL ,  BOSCH WERNER ,  LOTHERT THIMO

IPC: B05D20060101 ,  B05D3/02 ,  B05D7/00 ,  C08G18/42 ,  C08G18/80

CPC classification number: C08G18/8077 ,  B05D7/574 ,  B05D7/577 ,  C08G18/4288

Abstract: A process for producing multi-layer coatings comprising a waterborne primer-surfacer layer and a topcoat applied thereto on substrates, in which a waterborne primer-surfacer layer is applied from a waterborne primer-surfacer to substrates and baked and then a topcoat is applied, wherein the waterborne primer-surfacer has a binder solids content with a hydroxyl number of 100 to 250 mg KOH/g and contains free or blocked polyisocyanate as a curing agent (crosslinking agent) for the hydroxy-functional binder(s) in a molar ratio of OH/NCO of more than 2 : 1 to 5 : 1, and wherein, after it has been applied and before baking, the waterborne primer-surfacer layer is allowed to evaporate for 30 to 300 seconds at 15 to 40°C.

Abstract translation: 一种生产多层涂层的方法，包括水性底漆 - 表面层和在其上施涂到其上的面漆，其中将水性底漆 - 表面层从水性底漆 - 表面涂料施加到基材上并烘烤，然后涂布面漆， 其中所述水性底漆 - 二表面层具有羟基数为100至250mg KOH / g的粘合剂固体含量，并且含有游离或封闭的多异氰酸酯作为羟基官能粘合剂的固化剂（交联剂），摩尔比 的OH / NCO为2：1〜5：1，其中，涂布后，焙烧前，使水性底漆 - 表面层在15〜40℃下蒸发30〜300秒。

公开(公告)号：WO2005110622A2

公开(公告)日：2005-11-24

申请号：PCT/US2005/015273

申请日：2005-05-03

Applicant: E.I. DUPONT DE NEMOURS AND COMPANY ,  BECKER, Michael ,  BOSCH, Werner ,  LOTHERT, Thimo

Inventor： BECKER, Michael ,  BOSCH, Werner ,  LOTHERT, Thimo

IPC: B05D

CPC classification number: C08G18/8077 ,  B05D7/574 ,  B05D7/577 ,  C08G18/4288

Abstract: A process for producing multi-layer coatings comprising a waterborne primer-surfacer layer and a topcoat applied thereto on substrates, in which a waterborne primer-surfacer layer is applied from a waterborne primer-surfacer to substrates and baked and then a topcoat is applied, wherein the waterborne primer-surfacer has a binder solids content with a hydroxyl number of 100 to 250 mg KOH/g and contains free or blocked polyisocyanate as a curing agent (crosslinking agent) for the hydroxy-functional binder(s) in a molar ratio of OH/NCO of more than 2 : 1 to 5 : 1, and wherein, after it has been applied and before baking, the waterborne primer-surfacer layer is allowed to evaporate for 30 to 300 seconds at 15 to 40°C.

Abstract translation: 一种生产多层涂层的方法，包括水性底漆 - 表面层和在其上施涂到其上的面漆，其中将水性底漆 - 表面层从水性底漆 - 表面涂料施加到基材上并烘烤，然后涂布面漆， 其中所述水性底漆 - 二表面层具有羟基数为100至250mg KOH / g的粘合剂固体含量，并且含有游离或封闭的多异氰酸酯作为羟基官能粘合剂的摩尔比的固化剂（交联剂） 的OH / NCO为2：1〜5：1，其中，涂布后，焙烧前，使水性底漆 - 表面层在15〜40℃下蒸发30〜300秒。

公开(公告)号：WO2004008137A2

公开(公告)日：2004-01-22

申请号：PCT/EP2003/007449

申请日：2003-07-10

Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN ,  FICHTNER, Iduna ,  BECKER, Michael ,  BESADA PEREZ, Vladimir ,  CASTELLANOS, SERRA, Lila

Inventor： FICHTNER, Iduna ,  BECKER, Michael ,  BESADA PEREZ, Vladimir ,  CASTELLANOS, SERRA, Lila

IPC: G01N33/48

CPC classification number: G01N33/57415 ,  G01N33/5011

Abstract: The invention is about a method to diagnose and therapy breast tumors resistant to antiestrogen treatment by using specific target proteins and the nucleic acids encoding these proteins. The method is based on the determination of the differential expression of specific target genes on the nucleic acids and protein level in antiestrogen-resistant breast tumor cells. Fields of application exist in medicine and in the pharmaceutical industry. The method is characterized by the fact, that the concentration of at least one specific target protein is determined in tumor tissue and is compared with the standard reference value of the same protein or proteins in breast tumor tissue sensitive to antiestrogen treatment, whereat a protein concentration of the sample examined lying above the standard reference value indicates tumor resistance to antiestrogen treatment, provided it is a protein which is expressed at a higher level in breast tumor cells resistant to antiestrogen treatment, as compared to breast tumor cells sensitive to antiestrogen treatment, or a protein concentration of the sample examined lying below the standard reference value indicates tumor resistance to antiestrogen treatment, provided it is a protein which is expressed at a lower level in breast tumor cells resistant to antiestrogen treatment, as compared to breast tumor cells sensitive to antiestrogen treatment.

Abstract translation: 本发明涉及一种通过使用特异性靶蛋白和编码这些蛋白质的核酸来诊断和治疗耐抗雌激素治疗的乳腺肿瘤的方法。 该方法基于特异性靶基因在抗雌激素抗性乳腺肿瘤细胞中的核酸和蛋白质水平的差异表达的确定。 应用领域存在于医药和制药行业。 该方法的特征在于，在肿瘤组织中确定至少一种特异性靶蛋白的浓度，并将其与对抗雌激素治疗敏感的乳腺肿瘤组织中相同蛋白质或蛋白质的标准参考值进行比较，其中蛋白质浓度 与标准参考值相比高于标准参考值的样品表明，与抗雌激素治疗敏感的乳腺肿瘤细胞相比，具有抗雌激素治疗的肿瘤耐药性，只要它是对抗雌激素治疗有效的乳腺肿瘤细胞中较高水平表达的蛋白质，或 与标准参考值相比，检测的样品的蛋白质浓度表示抗肿瘤抗药性，只要它是对抗雌激素治疗敏感的乳腺肿瘤细胞的乳腺肿瘤细胞中较低水平表达的蛋白质。 治疗。

公开(公告)号：WO03023102A3

公开(公告)日：2003-10-09

申请号：PCT/EP0208764

申请日：2002-08-06

Applicant: BERGER SEIBA TECHNOTEX VERWALTUNGS GMBH & CO ,  TROENDLE BIRGIT ,  BECKER MICHAEL ,  HUBER NORBERT ,  ESCHBACH THOMAS

Inventor： TROENDLE BIRGIT ,  BECKER MICHAEL ,  HUBER NORBERT ,  ESCHBACH THOMAS

IPC: B60R21/16 ,  D03D1/02 ,  D03D11/00

CPC classification number: D03D11/00 ,  D03D1/02 ,  Y10T428/24025 ,  Y10T428/24562

Abstract: The invention relates to a method for weaving fabrics that comprise in at least some sections multiple layers, especially one-piece woven (OPW) airbags comprising single-layer, double-layer and multi-layer sections. According to the inventive method, weaves or weave combinations are produced in the double- or multi-layer sections that are different from the plain weave.

Abstract translation: 建议用单层，双层和多层区域，编织的方法至少部分地多层织物，在一块气囊尤其是机织（单件式织造= OPW），其特征在于，在从双语或多层范围 平纹编织不同或-bindungskombinationen进行编织。

公开(公告)号：WO2003072404A1

公开(公告)日：2003-09-04

申请号：PCT/EP2003/002030

申请日：2003-02-27

Applicant: HARMAN/BECKER AUTOMOTIVE SYSTEMS GMBH. ,  BECKER, Michael ,  LAPPE, Dirk ,  GIESEKE, Arnold

Inventor： BECKER, Michael ,  LAPPE, Dirk ,  GIESEKE, Arnold

IPC: B60R25/10

CPC classification number: G01C21/26

Abstract: A method of identifying an unauthorized use of a telematic device or a vehicle equipped therewith, the telematic device having an identification code, which is transmitted to a service provider comprising the step of storing at the service provider, the identification codes of those telematic devices, which have been reported as being used in unauthorized and the step of comparing identification codes received at the service provider for a match with the stored identification codes. The invention further relates to a corresponding system and telematic device for use in such system.

Abstract translation: 一种识别远程信息处理设备或其配备的车辆的未授权使用的方法，所述远程信息处理设备具有识别码，所述识别码被发送到服务提供商，包括在所述服务提供商处存储所述远程信息处理设备的识别码， 已被报告为未经授权的使用，以及将在服务提供商处接收的识别码与存储的识别码进行比较的步骤。 本发明还涉及用于这种系统的相应的系统和远程信息处理设备。

公开(公告)号：WO2003062251A1

公开(公告)日：2003-07-31

申请号：PCT/EP2003/000549

申请日：2003-01-21

Applicant: BASF AKTIENGESELLSCHAFT ,  VOLLAND, Martin ,  SEITZ, Verena ,  MAASE, Matthias ,  FLORES, Miguel ,  PAPP, Rainer ,  MASSONNE, Klemens ,  STEGMANN, Veit ,  HALBRITTER, Klaus ,  NOE, Ralf ,  BARTSCH, Michael ,  SIEGEL, Wolfgang ,  BECKER, Michael ,  HUTTENLOCH, Oliver

Inventor： VOLLAND, Martin ,  SEITZ, Verena ,  MAASE, Matthias ,  FLORES, Miguel ,  PAPP, Rainer ,  MASSONNE, Klemens ,  STEGMANN, Veit ,  HALBRITTER, Klaus ,  NOE, Ralf ,  BARTSCH, Michael ,  SIEGEL, Wolfgang ,  BECKER, Michael ,  HUTTENLOCH, Oliver

IPC: C07F9/22

CPC classification number: C07C403/12 ,  C07C1/30 ,  C07C45/50 ,  C07C51/412 ,  C07C51/58 ,  C07C67/14 ,  C07C2531/02 ,  C07C2601/16 ,  C07D295/185 ,  C07D317/36 ,  C07F9/142 ,  C07F9/145 ,  C07F9/46 ,  C07F9/4841 ,  C07F9/52 ,  C07F9/5721 ,  C07F9/5728 ,  C07F9/65038 ,  C07F9/65746 ,  C07F9/65848 ,  C07C47/02 ,  C07C13/23 ,  C07C69/78 ,  C07C69/24 ,  C07C69/14 ,  C07C53/10

Abstract: Verfahren zur Herstellung von Aminodihalogenphosphinen, Diaminohalogenphosphinen, Triaminophosphinen, Phosphorigsäuresterdiamiden, Aminophosphinen, Diaminophosphinen, Phosphorigsäuresteramidhalogeniden und Aminophosphinhalogeniden unter Abspaltung einer Säure und in Gegenwart einer Hilfsbase, wobei die Hilfsbase b) ein Salz mit der Säure bildet, das bei Temperaturen flüssig ist, bei denen das Wertprodukt während der Abtrennung des Flüssigsalzes nicht signifikant zersetzt wird und c) das Salz der Hilfsbase mit dem Wertprodukt oder der Lösung des Wertproduktes in einem geeigneten Lösungsmittel zwei nicht mischbare flüssige Phasen ausbildet.

Abstract translation: 一种用于制备Aminodihalogenphosphinen，Diaminohalogenphosphinen，Triaminophosphinen，Phosphorigsäuresterdiamiden，Aminophosphinen，Diaminophosphinen，Phosphorigsäuresteramidhalogeniden和Aminophosphinhalogeniden与消除酸的和在辅助碱，其中所述辅助底座B形成盐与作为液体的温度下的酸的存在下处理在对所需产物 没有液体盐和c的分离期间显著分解是与所需的产物或在合适的溶剂中形成两种不混溶的液相的所需产物的溶液中的辅助碱的盐。

公开(公告)号：WO2003029540A1

公开(公告)日：2003-04-10

申请号：PCT/EP2002/010851

申请日：2002-09-27

Applicant: BERGER SEIBA-TECHNOTEX VERWALTUNGS GmbH & Co. ,  BUSSKAMP, Heinz ,  BECKER, Michael ,  ESCHBACH, Thomas ,  HUBER, Norbert

Inventor： BUSSKAMP, Heinz ,  BECKER, Michael ,  ESCHBACH, Thomas ,  HUBER, Norbert

IPC: D03D15/00

CPC classification number: B26D5/005 ,  B26F1/3806 ,  D03D1/02 ,  D03D11/00 ,  D03D15/00 ,  D06H1/00 ,  D10B2401/16 ,  D10B2505/124 ,  Y10T83/0605 ,  Y10T83/2087

Abstract: Es wird ein Verfahren zum Herstellen von gewebten, insbesondere wenigstens teilweise mehrlagigen, Airbags vorgeschlagen, das folgende Verfahrenschritte enthält: a) Vorbereiten der Kettfäden in der Schärerei, wobei als Kennfäden geeignete Kettfäden für maschinenlesbare Markierungen bereits in der Kettschar untergebracht werden, b) Weben des Airbaggewebes, wobei als Kennfäden geeignete Schussfädden für maschinenlesbare Markiergungen über wenigstens einen Teil der Tuchbreite eingewebt werden, c) Ausschneiden der Airbags aus dem Airbaggewebe mit einer Schneidvorrichtung, wobei die Schneidvorrichtung von den eingewebten maschinenlesbaren Markierungen geführt wird.

Abstract translation: 它提出了一种方法，用于制造机织的，尤其是至少部分多层，安全气囊，以下方法步骤：a）制备经纱在整经店，使得在经已收容用于机器可读的标记，作为示踪剂合适经线，B）编织 气囊组织中，在布的宽度的至少一部分inwoven作为示踪剂合适Schussfädden用于机器可读Markiergungen，c）中切出从气囊织物切割装置的气囊，所述切割装置由交织机器可读标记被引导。

公开(公告)号：WO1998024784A1

公开(公告)日：1998-06-11

申请号：PCT/US1997022414

申请日：1997-12-01

Applicant: RHONE-POULENC RORER PHARMACEUTICALS INC. ,  EWING, William, R. ,  BECKER, Michael, R. ,  CHOI-SLEDESKI, Yong, Mi ,  PAULS, Heinz, W. ,  MCGARRY, Daniel, G. ,  DAVIS, Roderick, S. ,  SPADA, Alfred, P.

Inventor： RHONE-POULENC RORER PHARMACEUTICALS INC.

IPC: C07D403/02

CPC classification number: C07D207/273 ,  C07D205/085 ,  C07D207/14 ,  C07D207/416 ,  C07D211/76 ,  C07D223/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14

Abstract: The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Abstract translation: 式（I）化合物显示出有用的药理学活性，因此并入药物组合物中并用于治疗患有某些医学病症的患者。 更具体地说，它们是因子Xa活性的抑制剂。 本发明涉及式（I）化合物，含有式（I）化合物的组合物及其用途，其用于治疗患有或受生理条件影响的患者，其可以通过施用 因子Xa的活性抑制剂。

公开(公告)号：WO2013033206A2

公开(公告)日：2013-03-07

申请号：PCT/US2012/052854

申请日：2012-08-29

Applicant: UNIVERSITY OF ROCHESTER ,  FRISCH, Benjamin, J. ,  CALVI, Laura, M. ,  BECKER, Michael, W.

Inventor： FRISCH, Benjamin, J. ,  CALVI, Laura, M. ,  BECKER, Michael, W.

IPC: A61K48/00

CPC classification number: A01K67/027 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K38/17

Abstract: The present invention relates to the discovery that CCL3, through at least one of its receptors CCRl and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia. Interfering with the interaction between CCL3 and its receptors, by targeting at least one of CCL3, CCRl, CCR5, diminishes the effects of pathologies associated with myeloid neoplasms. In various embodiments, the myeloid neoplasm is a myeloproliferative disorder, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), or myelodysplasia syndrome (MDS).

Abstract translation: 本发明涉及CCL3通过其受体CCR1和CCR5中的至少一种在与骨髓瘤相关的病理学中发挥作用的发现。 在各种实施方案中，通过本文所述的本发明的组合物和方法治疗的与骨髓瘤相关的病理学包括但不限于破骨细胞/成骨细胞失衡，成骨细胞功能的抑制，骨丢失，造血的失调 干细胞微环境，异常造血恢复，全血细胞减少症，贫血症，血小板减少症，中性粒细胞减少症，双关节炎和红细胞减少症。 干扰CCL3与其受体之间的相互作用，通过靶向CCL3，CCR1，CCR5中的至少一种，减少与骨髓肿瘤相关的病理学的影响。 在各种实施方案中，骨髓瘤是骨髓增生性疾病，急性骨髓性白血病（AML），慢性骨髓性白血病（CML），慢性骨髓单核细胞白血病（CMML）或骨髓增生异常综合征（MDS）。